Weight Watchers adds FDA-approved Ozempic pill for type 2 diabetes to Med+ program

Weight Watchers has expanded its Med+ offering to include Novo Nordisk's FDA-approved Ozempic pill (semaglutide), a once-daily oral GLP-1 treatment for adults with type 2 diabetes. This addition provides members with a new medication option supported by clinical guidance, insurance navigation, and comprehensive diabetes care tools. The Ozempic pill complements Weight Watchers' existing diabetes support program, which includes tailored nutrition, coaching, and blood sugar tracking. This move aims to enhance member access to effective diabetes management within a clinically supported framework.